Gubra announces termination of collaboration with Bayer - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Tävling: Delta i Börskollens jultävling – vinn fina priser från Sonos och Börsdata

Pressmeddelande

Gubra announces termination of collaboration with Bayer

MFN Publicerad: 23 Aug 2023 16:44
Gubra

  • Gubra and Bayer started the collaboration in 2021
  • Gubra will actively (alone or with a new partner) continue further development of the cardio-renal metabolic peptide programme 
  • Gubra sees great potential for this drug programme within the area of healthy weight loss

 
Gubra today announced the termination of its cardio-renal peptide programme collaboration with Bayer AG. Bayer will return the asset following a portfolio review.
 
“We have matured the programme in a very short timeframe with a successful collaboration with Bayer, which is a testimony to the strength of our streaMLine peptide drug discovery engine,” said Henrik Blou, CEO of Gubra A/S. “We see great potential for developing the programme within ‘healthy weight loss,’ one of the other core areas at Gubra. With this recent news, we are now evaluating whether to proceed into further development ourselves or with a partner, but the programme definitely has a strong place in our pipeline.”
 
The peptide programme was licensed to Bayer in 2021 and Gubra was eligible to receive milestone payments and royalties on global sales which will no longer be the case as the programme is handed back. Gubra will communicate the potential of further development of this metabolic programme at a later stage when the different development and partnership options have been thoroughly evaluated.

Contacts at Gubra
Media: Sofia Pitt Boserup, [email protected], +45 4188 9586
Investors: Kristian Borbos, [email protected], +45 3080 8035

About Gubra
Gubra, founded in 2008 in Denmark, listed on NASDAQ Copenhagen in 2023, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 200 employees and had annual revenue of approx. DKK 200 million in 2022. See www.gubra.dk for more information.

This information is information that Gubra is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-08-23 16:44 CEST.

Attachments
Gubra announces termination of collaboration with Bayer

Bifogade filer

Gubra announces termination of collaboration with Bayerhttps://storage.mfn.se/31dd601e-f60a-4a5f-951b-195a5b2e642c/gubra-announces-termination-of-collaboration-with-bayer.pdf

Nyheter om Gubra

Läses av andra just nu

Om aktien Gubra

Senaste nytt